

EUPATI Sustaining Partners 2024

Sustaining Partner eligibility criteria:

To be part of the SPA, a partner needs to have committed substantially to the continuation of EUPATI through contributing in-cash or in-kind to the EUPATI 2023 Programme and beyond. All currently existing National Platforms are also considered as Sustaining Partners.

List of EUPATI 2024 Sustaining Partners:

Industry	Patient Organisations	Academia/Non-Profit	National Platforms
Abbvie	European AIDS Treatment Group (EATG)	Drug Information Association (DIA)	Austria
Amgen	European Federation of Allergy and Airways Diseases Patients' Associations (EFA)	European Infrastructure for Translational Medicine (EATRIS)	Belgium
AstraZeneca	European Liver Patients' Association (ELPA)	European Clinical Research Infrastructure Network (ECRIN)	Czech Republic
Bayer	European Patients' Forum (EPF)	European Forum for Good Clinical Practice (EFGCP)	Cyprus
Boehringer Ingelheim	Global Heart Hub (GHH)	European Organisation for Research and Treatment of Cancer (EORTC)	Denmark
Bristol-Myers Squibb	Parkinson's Europe	FindMeCure Foundation	Finland
Chiesi	The International Alliance of Dermatology Patient Organizations (GlobalSkin)	ISPOR	France
CSL Behring	The Irish Platform for Patient Organisations, Science and Industry (IPPOSI)	KU Leuven	Germany
Gilead		Medical University of Vienna	Greece
Greenphire		Sant Joan de Deu Research Institute	Ireland
GlaxoSmithKline		The Organisation for Professionals in Regulatory Affairs (TOPRA)	Italy
Incyte		South East Technological University (SETU)	Japan
Janssen		University College Dublin	Luxembourg
Lundbeck		University of Aveiro	Malta
Menarini		Vall d'Hebron University Hospital	Netherlands
MSD			Norway
Novartis			Poland
Novo Nordisk			Portugal
Novocure			Scotland
Pfizer			Slovakia
Roche			Spain
Servier			Sweden
Sobi			Switzerland
Takeda			Turkey
UCB			